• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Microchip imaging platform for roundworms could accelerate research

October 11, 2016 By Sarah Faulkner

roundworms-1x1Researchers developed a microchip imaging platform to image-analyze thousands of roundworms simultaneously, according to the Cockrell School of Engineering at the University of Texas at Austin. This is the 1st large-scale, in vivo drug discovery platform using a whole animal model, the school reported.

The study, published in Nature Communications, detailed a flexible, cellphone-sized chip with 96 wells used to immobilize drug-treated roundworms, commonly referred to as C. elegans. The chip can be used by researchers to analyze the efficacy of drugs on 3,600 live worms, at the cost of an in vitro, cell-based platform.

C. elegans are the 1st multicellular organisms to have a completely sequenced genome, the school reported. Because about 1/3 of C. elegans’ genes are the same as disease-causing genes in humans, the creatures serve as an effective model to evaluate the efficacy of drugs. The researchers at the University of Texas at Austin specifically focused on drugs that are indicated for neurodegenerative diseases, since the roundworms have full nervous systems and a diverse group of neurons.

“The C. elegans are thousands of times bigger than cells, so now that we have developed a way to capture and immobilize so many of them so quickly, we can determine much more information about the efficacy of drugs in a whole organism rather than the limited information that is derived when we used isolated individual cells,” lead researcher Adela Ben-Yakar said in prepared remarks.

They analyzed 1,000 drugs for treating protein aggregation, a characteristic of neurodegenerative diseases such as Huntington’s disease. “Four of the drugs we tested were effective at treating a protein aggregation model that is directly related to Huntington’s, and one of these drugs became even more effective at increased doses without causing toxicity,” Ben-Yakar said.

Ben-Yakar’s start-up company, Newormics, is developing a commercial product from the imaging prototype, according to the university.

Filed Under: Discovery, Featured, Imaging, Neurological, Research & Development Tagged With: University of Texas at Austin

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS